Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 vs Tislelizumab with Chemotherapy in First-line PD-L1 Negative NSCLC
NCT05990127Phase 3Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05990127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990127.